It would be very beneficial if the status of cancers could be determined from a blood specimen. However, peripheral blood leukocytes are very heterogeneous between individuals, and thus high-resolution technologies are likely required. We used cytometry by time-of-flight and next-generation sequencing to ask whether a plasma cell cancer (multiple myeloma) and related precancerous states had any consistent effect on the peripheral blood mononuclear cell phenotypes of patients. Analysis of peripheral blood samples from 13 cancer patients, 9 precancer patients, and 9 healthy individuals revealed significant differences in the frequencies of the T-cell, B-cell, and natural killer-cell compartments. Most strikingly, we identified a novel B-cell population that normally accounts for 4.0% AE 0.7% (mean AE SD) of total B cells and is up to 13-fold expanded in multiple myeloma patients with active disease. This population expressed markers previously associated with both memory (CD27 þ ) and na€ ve
Introduction
The human immune system has a unique role in cancer pathogenesis, modulating therapeutic responses, and disease outcome. Especially with emerging immune therapeutics and treatment regimens, the characterization of cancer-associated immunologic signatures has been of considerable interest. However, most studies of tumor "immunomes" rely on gene expression data and focus on the tumor microenvironment (1-3). To some extent, this may be due to the limited resolving power of standard cell analysis methods such as flow cytometry and the heterogeneity of peripheral blood cells. However, recent advances in cell phenotyping technology, particularly cytometry by time-offlight (CyTOF), which supports 40-label analysis (4) (5) (6) , and nextgeneration sequencing of immunoglobulin (Ig) genes (7, 8) , have greatly increased the possible depth of analysis at the single-cell level and expanded the resolving power of immune phenotyping tremendously. This suggests that it may be possible to detect disease-related immune signatures in human peripheral blood using these methods. As peripheral blood is readily and safely obtainable from almost any patient, finding useful signatures of disease in this type of specimen could be very valuable both clinically and in understanding the immune response to particular cancers at a systems biology level.
For this reason, we analyzed the peripheral blood of patients with hematopoietic cancer (multiple myeloma) and its corresponding precancer [asymptomatic myeloma and monoclonal gammopathy of undetermined significance (MGUS)]. Multiple myeloma, a malignancy of the B lineage, is characterized by the accumulation of clonal plasma cells in the bone marrow and the production of monoclonal Ig. The corresponding precancer diseases, MGUS and asymptomatic myeloma, are characterized by the production of monoclonal Ig and the lack of symptoms in often undiagnosed patients. They are not considered malignant because they do not always progress into multiple myeloma; however, patients have an approximate risk of 1% per year to develop multiple myeloma (9) , and many, if not all, multiple myeloma cases develop from a preceding MGUS or asymptomatic myeloma (10, 11) .
Multiple myeloma represents a prototypical disease model for tumor-microenvironment interactions (12, 13) , and recent studies of the multiple myeloma microenvironment have underlined its role in promoting tumor growth and survival (14) , as well as protection from T-cell responses (15) and chemotherapeutics (16, 17) . The myeloma cells "reprogram" their environment, influencing many chemokine and cytokine levels, including IL6, IL1a,perhaps its precursor diseases might have a significant impact on immune cells in the peripheral blood that could be detectable with these new technologies.
Here, we report that we have found major effects of multiple myeloma, but not MGUS or asymptomatic myeloma, that are detectable in peripheral blood cells of patients with active disease, in particular significant changes in the T-cell, B-cell, and natural killer (NK)-cell compartments, and most notably, the expansion of a novel, polyclonal B-cell subset.
Materials and Methods

Subjects
Thirteen multiple myeloma, 9 MGUS/asymptomatic myeloma patients (either untreated or without cancer-specific treatment during the last 6 months; Table 1 and Supplementary Table S1 ), and 5 treatment-na€ ve colorectal cancer patients ( Supplementary  Fig. S10 ) were recruited in accordance with federal and local human subjects regulations (Institutional Review Board protocol ID 25310). Nine age-and sex-matched healthy individuals were recruited through the Stanford Blood Center. The median ages of the multiple myeloma, precancer, and healthy control groups were 67, 69, and 68 years, respectively. Male subjects accounted for 54% in the cancer cohort, 56% in the precancer cohort, and 56% in the healthy control group.
PBMC preparation
Peripheral blood mononuclear cells (PBMC) were isolated from up to 40 mL of freshly drawn heparin anticoagulated blood using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB) centrifugation and resuspended in cell culture medium (Supplementary Table S2 ). Freshly isolated PBMCs were immediately used for in vitro stimulation and CyTOF staining; remaining cells were frozen after the addition of an equal volume of FBS containing 20% DMSO (both Sigma Aldrich).
Cell stimulation
For CyTOF, PBMCs were stimulated in 1 mL of cell culture medium containing 20 ng/mL phorbol 12-myristate 13-acetate (PMA), 1 mmol/L ionomycin (Sigma Aldrich), 5 mg/mL R848, or 3 mg/mL CpG ODN2216 (both InvivoGen) or left unstimulated for 6 hours. GolgiPlug (1 mL) and 0.7 mL GolgiStop (both BD Biosciences) were added at the beginning of the stimulation for PMA/ionomycin or to unstimulated samples, or added after 2 hours for R848 or after 3 hours for CpG ODN2216/DOTAP. DOTAP liposomal transfection reagent (Roche) was added at 1 mL/mL for CpG ODN2216 stimulation. Stimulation was done at 37 C and 5% CO 2 . For phosphorylation analysis, stimulation was done in reverse time order in 250 mL prewarmed cell culture medium containing 50 mmol/L CpG ODN2006 (InvivoGen), or 10 mg/mL goat antihuman IgM (Life Technologies) and 10 mg/mL goat F(ab)2 antihuman IgG (AbD Serotec). For B-cell receptor (BCR) stimulation, H 2 O 2 (MP Biomedicals) was added within 10 seconds after addition of the stimulating antibodies to a final concentration of 3.3 mmol/L.
CyTOF antibody labeling and staining
Purified antibodies were labeled using MaxPar DN3 kits (Fluidigm) and stored at 4 C at 0.2 mg/mL in W buffer (Fluidigm) containing antibody stabilizer (Candor). 
Cell signaling analysis
Cells were thawed, washed twice in prewarmed cell culture medium, and rested for 2 hours at 37 C with 5% CO 2 . Cells were washed in pure PBS and stained with zombie aqua (BioLegend), washed once in pure PBS and stained with CD24 and CD38 antibodies (Supplementary Table S4 ) for 15 minutes at 4 C. After washing in prewarmed cell culture medium, cells were resuspended in 250 mL of warm cell culture medium and immediately stimulated as described in the cell stimulation section. Stimulation was stopped by adding 150 mL of 4% PFA and incubated for 15 minutes at room temperature. Cells were washed with pure PBS and permeabilized in methanol at À80 C overnight. After washing twice in pure PBS, cells were stained with an intracellular staining cocktail of antibodies specific for phosphorylated signaling molecules and additional phenotyping markers (Supplementary Table S4 ), washed, and finally stained with AF488-labeled goat anti-rabbit antibody (Supplementary Table S4 ) before analysis on an LSRII flow cytometer (BD Biosciences).
Single-cell immunoglobulin sequencing
PBMCs were thawed and stained with fluorochromes according to Supplementary Table S4 . Single B cells were identified by their forward scatter/side scatter (FSC/SSC) characteristics, CD19, and CD20 expression and sorted into RT-PCR buffer in 96-well plates according to the gating strategy in Fig. 4A and Supplementary Fig. S8 . Ig genes were amplified and sequenced as previously described (7, 8) .
FISH
Cells were stained as described for single-cell Ig sequencing and bulk sorted according to the gating scheme in Supplementary Fig.  S8 . Cells were stained with Vysis LSI CCND1 and Vysis LSI IGH probes (both Abbott Molecular) according to the standard protocols, and 200 cells per population (105 for CD19
Cytometry data analysis and statistics All two-dimensional gating analysis was done using FlowJo (Treestar). For heatmaps (Figs. 1A and 5; Supplementary Figs. S2 and S9), data in FlowJo-exported tables were trimmed to the 95th and 5th percentiles per gated population and visualized using heatmap.2 (gplots version 2.11.0). Principal component analysis (PCA) was done using prcomp (stats version 2.15.3) and visualized with ggplot2 (version 0.9.3.1) and scatterplot3d (version 0. .
For statistics in scatterplots ( Fig. 2B and Supplementary Fig.  S3 ), we used ANOVA. P values were adjusted using the Benjamini-Hochberg correction, and all differences that reached q values below 0.05 were followed up with TukeyHSD, the results of which are indicated as P values in the respective plots. All statistics were done in R version 2.15.3 (18) .
Citrus version 0.05 (https://github.com/nolanlab/citrus; ref. 19 ) was used on all healthy control and all multiple myeloma samples. Each file was pregated on live CD45
þ cells in FlowJo. The file sample size was set to 10,000 events and CD33, CD4, CD20, CD8, CD16, CD19, CD11c, CD24, CD10, CD1c, CD14, CCR7, CD7, CD28, CD5, CD38, CD45RA, CD123, CD45RO, CD56, HLA-DR, CD25, TCR-ab, and CD127 were used as clustering markers. Median differences (median columns) were calculated for IgM, CD57, IgD, CD27, CCR7, CD28, TNFa, IL17A, and HLA-DR. The minimum cluster size was set to 0.02%, and Significance Analysis of Microarrays (SAM) was used as model type.
Results
Phenotypic diversity of PBMC subsets in multiple myeloma
We used CyTOF with a 39-marker panel (Supplementary  Table S3 ) to analyze the human immune system in freshly isolated PBMCs from multiple myeloma patients, from precancer MGUS and asymptomatic myeloma patients (Table 1  and Supplementary Table S1 ), and from healthy individuals. Frequencies of all major PBMC subsets and their cytokine expression patterns were determined by two-dimensional gating as percentages of the corresponding parent populations in four different stimulus conditions (see Supplementary Fig. S1 and Supplementary Table S5 for typical gating and a list of all applied gates).
We visualized cell frequencies in each of the 244 two-dimensional gates in a heatmap representing the immune phenotypic diversity in the peripheral blood of patients with multiple myeloma, precancer patients, and healthy controls (Fig. 1A ). Samples were arranged by disease group, and no clustering was applied to the columns. Emphasizing the phenotypic heterogeneity of the dataset, sample clustering by Euclidian distances of relative cell frequencies did not lead to the formation of clear clusters for cancer patients, precancer patients, and healthy individuals (Supplementary Fig. S2 ).
The direct comparison of individual population frequencies between disease groups revealed significant differences in the
þ CD45RA þ ab and regulatory) and B lymphocyte (total, CD27 þ , and transitional) compartments in different stimulus conditions as summarized in Supplementary  Fig. S3 .
To analyze whether individual markers or combinations of those could distinguish cancer samples from precancer or healthy samples, we applied PCA to cell frequencies in the same 244 twodimensional gates. The first four principal components described close to 50% of the variance in our dataset (Fig. 1B) , and plotting principal components one to three confirmed phenotypic heterogeneity in samples from the cancer group, whereas the precancer and healthy control samples tended to cluster (Fig. 1C and  D) . Nevertheless, PC1 separated a subset of cancer samples from precancer and healthy donor samples. The loadings for PC1 were dominated by ab T-cell gates, including costimulatory molecules (CD28), and markers that have been associated with T-cell exhaustion (CD57), or homing (CCR7), both on CD4 þ and CD8 þ T cells (Fig. 1E) . Surprisingly, CD19
and expression of CD27 contributed to PC1 across different stimuli conditions (unstimulated and after PMA/ionomycin stimulation, Fig. 1E , in red). This population was particularly interesting because it combined two markers (CD24 lo CD38 þ ) that have been associated with the na€ ve stage of B-cell differentiation (20) , and CD27, which is associated with memory B cells (21) . This is a novel phenotype that has not been reported previously. Fig. 2A and B) . Notably, the expression of CD27 on CD24 lo CD38 þ B cells in multiple myeloma samples showed a very broad range (5.3%-66.6%) with samples clustering at the high and low ends of this distribution, suggesting the existence of two patient populations (Fig. 2B , shaded in gray). This dichotomy was already noted in the PCA, where PC1 separated only a subset of multiple myeloma samples from precancer and healthy control samples (Fig. 1C) . Nevertheless, the frequency of CD24 lo CD38 þ CD27 þ B cells was significantly higher in multiple myeloma samples than in precancer samples (P ¼ 0.005) and never exceeded 10% in Supplementary Fig. S4 ). Notably, none of the patients were diagnosed with plasma cell leukemia or showed phenotypic characteristics of malignant or de-differentiated plasma cells in the CD24 lo CD38 þ gate ( Fig.   2A and Supplementary Fig. S5 ). Given the 39-dimensional space of our CyTOF dataset, twodimensional gating fails to capture the richness that comes from including all possible marker combinations. We therefore used a new analysis method, Citrus (19) , for the identification of significantly different marker expressions on cell populations from high-dimensional data from multiple myeloma patients and healthy individuals ( Fig. 2C and Supplementary Fig. S6 ). Among the different expression levels of CD57 on T-cell and NK-cell subsets ( Supplementary Fig. S6B and S6C), Citrus detected significantly higher CD27 levels in two B-cell subsets (Fig. 2C ). Cluster A (Fig. 2C) showed lower CD24 expression and therefore most likely represents the CD38 þ CD24 lo B-cell subset identified with two-dimensional gating and PCA.
Taken together, CyTOF data analyzed using two different methods enabled us to identify a uniquely expanded B-cell population with aberrant expression levels of CD24, CD38, and CD27 in the peripheral blood of many multiple myeloma patients (Fig. 2B ). This population was not evident in MGUS or asymptomatic myeloma patients and healthy individuals.
We then verified these findings with flow cytometry, analyzing PBMCs from all multiple myeloma samples, which confirmed the expansion of the CD24 lo CD38 Supplementary   Fig. S7 ). In addition, we also analyzed IgA, IgM, and IgD expression levels on B-lineage cells, and serum levels of IgG, IgA, IgM, kappa, and lambda immunoglobulin light chains ( Fig. 3 and 
cells from 2 multiple myeloma patients (sort gates in Fig. 4A ).
In total, light chain sequences from 93 individual cells were sequenced and further analyzed. Both patients used a variety of different V region genes that partly overlapped between patients ( Fig. 4B and C) . The direct comparison of individual cells' Ig sequences within the same sample revealed 8 cells in subject 7 and 7 cells in subject 11 whose sequences occurred twice (Fig. 4D) . Nevertheless, based on different Ig sequences and the variety of V regions used, the CD24 lo CD38 þ CD27 þ B-cell compartment has to be considered polyclonal, although an underlying antigendriven process responsible for the expansion of this B-cell subset is possible. Notably, there were no identical sequences across both patients.
We detected an average of 18 (subject 7) or 14 (subject 11) somatic mutations per V region, 5 (subject 7) and 3 (subject 11) of which were silent and 13 (subject 7) or 11 (subject 11) were nonsilent mutations. None of the V region sequences were germline in either patient (Fig. 4E) , a further indication that this B-cell subset is a memory population.
To further strengthen the case that the investigated B-cell populations are not directly related to the malignant plasmacell clone, we FACS-sorted bulk Supplementary Fig. S8 ) from 1 patient whose malignant plasma-cell population contained the t (11;14) . Sorted cells were analyzed with FISH, and the t(11;14) could not be detected in any of these populations ( Supplementary  Fig. S8 ). The unpaired two-sided Wilcoxon rank-sum test was used to calculate the P value. Raw data for this figure are included in 
CD38
À and CD24 lo CD38 þ populations respectively after staining without fixation/permeabilization, as shown by the predominant expression of CD27 on CD24 hi (memory) B cells in healthy individuals after methanol permeabilization (Supplementary Fig. S9A ). Phosphorylation responses to anti-human IgG/IgM or TLR9 ligand CpG ODN2006 stimulation were clearly distinguishable from baseline phosphorylation, as shown in Fig. 5B .
No significant phosphorylation was detectable at baseline in any subpopulations of unstimulated B cells. The addition of H 2 O 2 resulted in slightly increased phosphorylation over time that was most pronounced in ERK and p38 (Fig. 5C) . Interestingly, total CD27 þ and CD24 lo CD27 þ B cells showed very similar phosphorylation levels in both healthy individuals and PBMCs from multiple myeloma patients. Stimulation with CpG ODN2006 or anti-human IgG/IgM elicited up to 21-fold higher phosphorylation when compared with that of H 2 O 2 controls ( Fig. 5D and E) . The unique phosphorylation patterns of CD27 þ , CD27
À , and total B-cell populations were consistent at baseline and after stimulation, suggesting essentially different intracellular signaling responses in these subsets; however, significant differences between healthy and multiple myeloma B-cell phosphorylation levels could be detected neither at baseline nor after stimulation. Overall, CpG ODN2006 stimulation caused mostly ERK phosphorylation, whereas BCR stimulation elicited predominantly SYK and p38 phosphorylation in the analyzed populations (Fig. 5E) . The unique phosphorylation patterns of CD27 þ , CD27 À , and total B-cell subsets at baseline and after BCR stimulation were confirmed in two additional sample pairs (Supplementary Fig. S9 ).
Discussion
In this study, we present high-dimensional cytometry data on the human immunologic landscape of peripheral blood cells across most of the known developmental stages of multiple myeloma (multiple myeloma, asymptomatic myeloma, MGUS, and healthy individuals). We manually determined the frequencies of all major PBMC subsets (ab T, gd T, B, NK, myeloid dendritic cells, plasmacytoid dendritic cells, and monocytes) and the expression of additional phenotypic and functional markers in four different stimulus conditions. With 434 two-dimensional initial gates per sample, to the best of our knowledge, this is the most detailed phenotypic and functional analysis of PBMC subsets in this disease. After removing mutually exclusive gates (e.g., from CD38
þ was kept), 244 of these gates (listed in Supplementary Table   S5 ) were used for statistical analyses and data visualization. Cell frequencies in each of these gates were compared between disease groups, one at a time, and using PCA. The manual comparisons allowed a very detailed view of particular cell subsets. Elevated numbers of CD57 Supplementary Fig.   S3A ) could be expected given the previous work of Sze and colleagues (24) ; cells sharing this phenotype are considered to be clonally restricted and associated with a favorable disease outcome. In addition, we detected lower numbers of regulatory T cells (Treg) in the peripheral blood of multiple myeloma patients ( Supplementary Fig. S3A ). In multiple myeloma, the Treg/Th17 balance correlates with disease outcome (25, 26) ; however, differences in frequencies of IL17-producing cells between patients with multiple myeloma, precancer patients, and healthy individuals did not reach statistical significance, and Treg Supplementary Fig. S7 . Serum K and L levels of the predominant light chain are printed in bold. Clinical data for each subject can be found in Table 1 .
frequencies in the peripheral blood of multiple myeloma patients are a matter of debate (26, 27) . We detected significantly lower B-cell frequencies in total leukocytes of multiple myeloma patients when compared with those in healthy individuals (Supplementary Fig. S3A ). In a study involving hundreds of patients, low CD19 þ cell frequencies have been associated with an advanced disease stage and higher B-cell numbers with a better prognosis of multiple myeloma (28) . The Fig. S3A ) as shown along with all other direct subset comparisons in Supplementary Fig. S3B .
The most striking finding was the selective expansion of CD24 (20, 31) . Citrus is a new analysis tool that compares marker expression in individual multidimensional cell clusters between sample groups in a statistically rigorous fashion (19) . Besides differences in CD27 expression on B-cell subsets (Fig. 2C) , Citrus confirmed differences in CD57 expression on T-cell and NK-cell subsets ( Supplementary Fig. S6B and S6C ). Automated gating/ clustering strategies confirmed our findings from data analystinfluenced manual gating with high statistical significance (false discovery rate < 0.01), but did not add any categorically new findings. Thus, the two-dimensional analysis approach even in this 39-dimensional dataset was still able to reveal most of the significant differences between sample groups, although it could not address all marker combinations on every single cell. The advantages of Citrus are represented in the "unsupervised" nature of the approach and the enormous reduction of analysis time.
Multiple myeloma plasma cells are usually not highly proliferative, and the dividing multiple myeloma precursor pool is assumed to comprise post-germinal-center B cells (31) (32) (33) (34) , which could match the phenotype of CD24 lo CD38 þ CD27 þ B cells ( Supplementary Fig. S4 ). Yet, the existence and phenotype of clonotypic B cells in the peripheral blood of multiple myeloma patients is still a matter of debate (33, (35) (36) (37) . Taking into account the phenotype of CD24 lo CD38 þ CD27 þ B cells ( Fig. 2A and Supplementary Fig. S5 ), the polyclonality of immunoglobulin genes, and the absence of multiple myeloma clone-specific translocations ( Supplementary Fig. S8 ), this B-cell population is unlikely to be directly derived from or preceding the multiple myeloma plasma-cell population. 
